Endometriosis – Pipeline Assessment and Market Forecasts to 2017
The industry analysis specialist, has released its new report, “Endometriosis – Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global endometriosis market. The report identifies the key trends shaping and driving the global endometriosis market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global endometriosis sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
estimates that the global endometriosis market was valued at $785m in 2009 and will grow at a Compound Annual Growth Rate (CAGR) of 4.3% to reach $1.1 billion by 2017. This modest growth forecast is primarily attributed to a weak pipeline landscape. The existing market is weak due to a lack of diagnostic techniques, disease awareness and the poor safety and efficacy profiles of the existing therapies. There is a high unmet need which is largely driven by the availability of drugs that are moderately successful in terms of safety and efficacy. The endometriosis market is primarily formed of generic and off-label drugs and has very few approved drugs which fall in the major therapeutic categories such as NSAIDs, oral contraceptives, GnRH agonists and progestins.
Scope
The report provides information on the key drivers and challenges of the endometriosis market. Its scope includes:
– Annualized global endometriosis market revenues data from 2001 to 2009, forecast for eight years to 2017.
– Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as GnRH antagonists, GnRH synergists, aromatase inhibitors, antiprogestins and steroid sulfatase inhibitors.
– Analysis of the current and future competition in the global endometriosis market. Key market players covered are Bayer Healtcare Pharmaceuticals, Pfizer Inc, Neurocrine Biosciences Inc., Æterna Zentaris Inc. and Repros Therapeutics Inc.
– Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
– Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the endometriosis therapeutics market.
For more information, please contact :
http://www.aarkstore.com/reports/Endometriosis-Pipeline-Assessment-and-Market-Forecasts-to-2017-37925.html
Related Reports
Endometriosis – Pipeline Review, Q1 2011
Endometriosis Therapy Pipeline Report
Endometriosis – Pipeline Assessment and Market Forecasts to 2017
Endometriosis – Pipeline Review, Q4 2010
Endometriosis Therapy Area Pipeline Report
Endometriosis Therapy Area Pipeline Report
Endometriosis Pipeline Assessment and Market Forecasts to 2017
Women’s Health Endometriosis Therapy Area Pipeline Report
Women’s Health Endometriosis Therapy Area Pipeline Report
Pipeline Insight: Endometriosis – New therapies near market while more innovative targets still needed
Contact : Minu
Aarkstore Enterprise
Tel : +912227453309
Mobile No: +919272852585
Email :[email protected]
Website : http://www.aarkstore.com
